MedPath

Tanvex Biopharma Receives Second CRL from FDA for Herceptin Biosimilar TX-05

7 months ago1 min read

Key Insights

  • Tanvex Biopharma U.S.A. Inc. received a second Complete Response Letter (CRL) from the FDA on January 3 for its TX-05 Biologics License Application (BLA).

  • The CRL identifies issues that must be resolved by the third-party manufacturer responsible for producing Tanvex's TX-05 drug product.

  • TX-05 is a biosimilar referencing Roche's Herceptin (trastuzumab), a medication used in the treatment of HER2-positive breast cancer and gastric cancer.

Tanvex Biopharma Inc. has announced that its U.S. subsidiary, Tanvex Biopharma U.S.A. Inc., received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 3 regarding its Biologics License Application (BLA) for TX-05, a biosimilar referencing Roche's Herceptin (trastuzumab). This marks the second CRL issued for TX-05.
The FDA's CRL cites issues that need to be addressed by the downstream manufacturer of TX-05. The manufacturer is a third-party service provider responsible for the drug product's production.
Herceptin (trastuzumab) is a monoclonal antibody targeting the HER2 receptor, widely used in treating HER2-positive breast cancer and gastric cancer. Biosimilars like TX-05 aim to provide more affordable treatment options, expanding access to these life-saving therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.